JP2008536487A5 - - Google Patents

Download PDF

Info

Publication number
JP2008536487A5
JP2008536487A5 JP2008501411A JP2008501411A JP2008536487A5 JP 2008536487 A5 JP2008536487 A5 JP 2008536487A5 JP 2008501411 A JP2008501411 A JP 2008501411A JP 2008501411 A JP2008501411 A JP 2008501411A JP 2008536487 A5 JP2008536487 A5 JP 2008536487A5
Authority
JP
Japan
Prior art keywords
cells
activated
tumor cell
atcp
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008501411A
Other languages
English (en)
Japanese (ja)
Other versions
JP5663135B2 (ja
JP2008536487A (ja
Filing date
Publication date
Priority claimed from GB0505508A external-priority patent/GB0505508D0/en
Priority claimed from GB0514288A external-priority patent/GB0514288D0/en
Application filed filed Critical
Priority claimed from PCT/GB2006/000960 external-priority patent/WO2006097743A2/en
Publication of JP2008536487A publication Critical patent/JP2008536487A/ja
Publication of JP2008536487A5 publication Critical patent/JP2008536487A5/ja
Application granted granted Critical
Publication of JP5663135B2 publication Critical patent/JP5663135B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2008501411A 2005-03-17 2006-03-16 腫瘍細胞調製物によってｉｎｖｉｔｒｏでナチュラルキラー細胞を活性化させるための方法 Expired - Fee Related JP5663135B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0505508.2 2005-03-17
GB0505508A GB0505508D0 (en) 2005-03-17 2005-03-17 Method
GB0514288A GB0514288D0 (en) 2005-07-12 2005-07-12 Method
GB0514288.0 2005-07-12
PCT/GB2006/000960 WO2006097743A2 (en) 2005-03-17 2006-03-16 Method for actvating natural killer cells by tumor cell preparation in vitro

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2012224042A Division JP5906168B2 (ja) 2005-03-17 2012-10-09 腫瘍細胞調製物によってｉｎｖｉｔｒｏでナチュラルキラー細胞を活性化させるための方法
JP2014212302A Division JP2015012876A (ja) 2005-03-17 2014-10-17 腫瘍細胞調製物によってｉｎｖｉｔｒｏでナチュラルキラー細胞を活性化させるための方法

Publications (3)

Publication Number Publication Date
JP2008536487A JP2008536487A (ja) 2008-09-11
JP2008536487A5 true JP2008536487A5 (enExample) 2009-03-12
JP5663135B2 JP5663135B2 (ja) 2015-02-04

Family

ID=36992099

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2008501411A Expired - Fee Related JP5663135B2 (ja) 2005-03-17 2006-03-16 腫瘍細胞調製物によってｉｎｖｉｔｒｏでナチュラルキラー細胞を活性化させるための方法
JP2012224042A Expired - Lifetime JP5906168B2 (ja) 2005-03-17 2012-10-09 腫瘍細胞調製物によってｉｎｖｉｔｒｏでナチュラルキラー細胞を活性化させるための方法
JP2014212302A Withdrawn JP2015012876A (ja) 2005-03-17 2014-10-17 腫瘍細胞調製物によってｉｎｖｉｔｒｏでナチュラルキラー細胞を活性化させるための方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2012224042A Expired - Lifetime JP5906168B2 (ja) 2005-03-17 2012-10-09 腫瘍細胞調製物によってｉｎｖｉｔｒｏでナチュラルキラー細胞を活性化させるための方法
JP2014212302A Withdrawn JP2015012876A (ja) 2005-03-17 2014-10-17 腫瘍細胞調製物によってｉｎｖｉｔｒｏでナチュラルキラー細胞を活性化させるための方法

Country Status (9)

Country Link
US (3) US8257970B2 (enExample)
EP (2) EP1863905B1 (enExample)
JP (3) JP5663135B2 (enExample)
AU (1) AU2006224313B2 (enExample)
CA (1) CA2601197C (enExample)
DK (1) DK1863905T3 (enExample)
ES (1) ES2566335T3 (enExample)
PL (1) PL1863905T3 (enExample)
WO (1) WO2006097743A2 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007238660C1 (en) 2006-04-14 2013-11-07 Astellas Institute For Regenerative Medicine Hemangio-colony forming cells
RU2517719C2 (ru) * 2008-05-29 2014-05-27 Трансжене Са Биомаркер для отбора пациентов и соответствующие способы
CN102575230A (zh) * 2009-07-10 2012-07-11 马克·洛戴尔 活化的nk细胞的经保存的组合物及其使用方法
US8961956B2 (en) 2011-11-30 2015-02-24 Ocata Therapeutics, Inc. Mesenchymal stromal cells and uses related thereto
PL2785359T3 (pl) 2011-11-30 2018-12-31 Astellas Institute For Regenerative Medicine Mezenchymalne komórki zrębowe i związane z nimi zastosowania
WO2013132256A1 (en) 2012-03-07 2013-09-12 Ucl Business Plc Compositions and methods for treating viral-mediated infection and disease in immunocompromised individuals
WO2013168978A1 (ko) * 2012-05-07 2013-11-14 고려대학교 산학협력단 말초혈액단핵구 유래 자연 살해세포의 유도 및 증식 방법
KR101520534B1 (ko) 2012-05-07 2015-05-21 고려대학교 산학협력단 말초혈액단핵구 유래 자연 살해세포의 유도 및 증식 방법
CN104471059B (zh) 2012-07-12 2018-04-17 珠海横琴爱姆斯坦生物科技有限公司 人胚胎干细胞衍生的间充质样干细胞、方法及其应用
CA2896053A1 (en) 2012-12-21 2014-06-26 Ocata Therapeutics, Inc. Methods for production of platelets from pluripotent stem cells and compositions thereof
BR112017004270B1 (pt) * 2014-09-04 2023-03-07 Stemcell Technologies Inc Método de ativação de células t ou células nk
US10758567B2 (en) 2015-09-16 2020-09-01 Immune Ventures LLC In vivo priming of natural killer cells
ES2871100T3 (es) * 2015-12-07 2021-10-28 Immune Ventures LLC Cebado in vivo de linfocitos citolíticos naturales
EP3596201A4 (en) * 2017-03-15 2020-12-09 Immune Ventures, LLC IN VIVO PRIMING OF NATURAL KILLER CELLS
CN115710576A (zh) 2018-02-01 2023-02-24 Nkmax有限公司 产生天然杀伤细胞的方法和用于治疗癌症的组合物
WO2020047333A1 (en) 2018-08-30 2020-03-05 HCW Biologics, Inc. Single-chain chimeric polypeptides and uses thereof
CA3109139A1 (en) * 2018-08-30 2020-03-05 HCW Biologics, Inc. Methods of treating aging-related disorders
CN112996805A (zh) 2018-08-30 2021-06-18 Hcw生物科技公司 多链嵌合多肽和其用途
JP6838750B2 (ja) * 2019-01-21 2021-03-03 株式会社ガイアバイオメディシン Ｎｋ細胞を含む細胞集団の製造方法
AU2020294797B2 (en) 2019-06-21 2025-12-18 Immunitybio, Inc. Multi-chain chimeric polypeptides and uses thereof
WO2021163299A1 (en) 2020-02-11 2021-08-19 HCW Biologics, Inc. Chromatography resin and uses thereof
CA3169243A1 (en) 2020-02-11 2021-08-19 HCW Biologics, Inc. Methods of activating regulatory t cells
CN116670163A (zh) 2020-02-11 2023-08-29 Hcw生物科技公司 治疗年龄相关疾病和炎性疾病的方法
AU2021262794B2 (en) 2020-04-29 2026-06-18 Immunitybio, Inc. Anti-CD26 proteins and uses thereof
US12024545B2 (en) 2020-06-01 2024-07-02 HCW Biologics, Inc. Methods of treating aging-related disorders
US12594323B2 (en) 2022-04-13 2026-04-07 Immunitybio, Inc. Methods of reducing neuroinflammation
CN120153065A (zh) * 2022-08-03 2025-06-13 自然免疫生物公司 人类t细胞急性淋巴母细胞白血病细胞系及其用于治疗癌症的应用
KR20250118299A (ko) * 2024-01-29 2025-08-06 인하대학교 산학협력단 전기자극 시스템을 활용한 자연살해세포의 암세포 살상 능력 증진 방법

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69834257T2 (de) * 1997-04-30 2007-01-04 Klingemann, Hans Natürliche killerzelllinien und verfahren zu ihrer verwendung
US6849452B1 (en) * 1998-03-03 2005-02-01 Institut Gustave Roussy Methods for activating natural killer (NK) cells and means for carrying out said methods
US7662387B2 (en) 2003-02-20 2010-02-16 Seattle Genetics Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
US7435596B2 (en) * 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell

Similar Documents

Publication Publication Date Title
Ginckels et al. Oxidative stress and inflammation in cardiovascular diseases and cancer: role of non-coding RNAs
Nehrbas et al. Extracellular vesicles and chemotherapy resistance in the AML microenvironment
Pancione et al. Immune escape mechanisms in colorectal cancer pathogenesis and liver metastasis
Zorzi et al. A phase I study of histone deacetylase inhibitor, pracinostat (SB939), in pediatric patients with refractory solid tumors: IND203 a trial of the NCIC IND program/C17 pediatric phase I consortium
Liu et al. PAMAM dendrimers mediate siRNA delivery to target Hsp27 and produce potent antiproliferative effects on prostate cancer cells
NO20075245L (no) Eliminasjon av heterogen eller blandet cellepopulasjon i tumorer
Montoya et al. Development of a novel formulation with hypericin to treat cutaneous leishmaniasis based on photodynamic therapy in in vitro and in vivo studies
MX2010010726A (es) Composicion de estilizado de cabello.
Wang et al. Exercise training preserves ischemic preconditioning in aged rat hearts by restoring the myocardial polyamine pool
BRPI0612612A2 (pt) compàsitos de celulose reconstituÍdos por lÍquido iânico como matrizes de suporte sàlido
JP2016501013A5 (enExample)
Li et al. ADAR1 attenuates allogeneic graft rejection by suppressing miR‐21 biogenesis in macrophages and promoting M2 polarization
JP2009507918A5 (enExample)
JP2008519047A5 (enExample)
NZ599825A (en) Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells
JP2009232853A5 (enExample)
Kanat et al. Shattering the castle walls: Anti-stromal therapy for pancreatic cancer
JP2009545620A5 (enExample)
WO2017087947A3 (en) Method of treatment of follicular lymphoma with a btk inhibitor
Berg et al. Microbes, macrophages, and melanin: a unifying theory of disease as exemplified by cancer
Ziko et al. Mechanical Stress Promotes Cisplatin‐Induced Hepatocellular Carcinoma Cell Death
Huart et al. Could protons and carbon ions be the silver bullets against pancreatic cancer?
Kim et al. A3 adenosine receptor antagonist, truncated Thio-Cl-IB-MECA, induces apoptosis in T24 human bladder cancer cells
WO2017200492A1 (en) Method of treating cancer
WO2020060779A3 (en) Methods and compositions for treating laminopathies affecting skeletal or cardiac muscle